ONLY IDELVION IS FDA APPROVED FOR 7- AND 14-DAY DOSING
Two dosing schedules that meet your patient's individual needs
Choose the regimen that’s right for your patients and adjust based on their clinical condition and response.
*In patients 12 years and older on a weekly dose of ≤40 IU/kg for 1 month while not requiring dose adjustments or experiencing spontaneous bleeding.
| Type of Bleeding Episode | Circulating Factor IX Activity Required (% or IU/dL) | Frequency of Dosing (hours) | Duration of Therapy (days)† |
|---|---|---|---|
| MINOR OR MODERATE Uncomplicated hemarthrosis, muscle bleeding (except iliopsoas) or oral bleeding | 30–60 | 48–72 | At least 1 day, until bleeding stops and healing is achieved. Single dose should be sufficient for majority of bleeds. |
| MAJOR Life or limb threatening hemorrhage, deep muscle bleeding, including iliopsoas, intracranial, retropharyngeal | 60–100 | 48–72 | 7–14 days, until bleeding stops and healing is achieved. Maintenance dose weekly. |
| Type of Bleeding Episode | |
| MINOR OR MODERATE Uncomplicated hemarthrosis, muscle bleeding (except iliopsoas) or oral bleeding | MAJOR Life or limb threatening hemorrhage, deep muscle bleeding, including iliopsoas, intracranial, retropharyngeal |
| Circulating Factor IX Activity Required (% or IU/dL) | |
| 30–60 | 60–100 |
| Frequency of Dosing (hours) | |
| 48–72 | 48–72 |
| Duration of Therapy (days)† | |
| At least 1 day, until bleeding stops and healing is achieved. Single dose should be sufficient for majority of bleeds. | 7–14 days, until bleeding stops and healing is achieved. Maintenance dose weekly. |
| Type of Surgery | Circulating Factor IX Activity Required (% or IU/dL) | Frequency of Dosing (hours) | Duration of Therapy (days)† |
|---|---|---|---|
| MINOR (including uncomplicated tooth extraction) | 50–80 | 48–72 | At least 1 day, or until healing is achieved. Single dose should be sufficient for a majority of minor surgeries. |
| MAJOR (including intracranial, pharyngeal, retropharyngeal, retroperitoneal) | 60–100 (initial level) |
48–72 | 7–14 days, or until bleeding stops and healing is achieved. Repeat dose every 48–72 hours for the first week or until healing is achieved. Maintenance dose 1–2 times per week. |
| Type of Surgery | |
| MINOR (including uncomplicated tooth extraction) | MAJOR (including intracranial, pharyngeal, retropharyngeal, retroperitoneal) |
| Circulating Factor IX Activity Required (% or IU/dL) | |
| 50–80 | 60–100 (initial level) |
| Frequency of Dosing (hours) | |
| 48–72 | 48–72 |
| Duration of Therapy (days)† | |
| At least 1 day, or until healing is achieved. Single dose should be sufficient for a majority of minor surgeries. | 7–14 days, or until bleeding stops and healing is achieved. Repeat dose every 48–72 hours for the first week or until healing is achieved. Maintenance dose 1–2 times per week. |
†Adapted from the WFH Guidelines for the Management of Hemophilia.
More vial sizes may mean less to reconstitute and infuse
5 vial sizes for optimal flexibility and efficiency
- A range of sizes to facilitate the regimen you choose
- Reconstituting is fast and simple using the Mix2Vial® needle-free reconstitution and transfer system
No refrigeration required
- May be stored at room temperature or in refrigerator (36°F–77°F). Do not freeze
- Do not store past expiration date printed on carton and vial
KIT NDC: 69911-864-02 2.5-mL diluent
KIT NDC: 69911-865-02 2.5-mL diluent
KIT NDC: 69911-866-02 2.5-mL diluent
KIT NDC: 69911-867-02 5-mL diluent
KIT NDC: 69911-869-02 5-mL diluent
Images are representations, not actual depictions of actual vials.
Mix2Vial® is a registered trademark of West Pharma Services IL, Ltd., a subsidiary of West Pharmaceuticals Services, Inc.
When switching to IDELVION, Ray made the transition from on-demand to an extended prophylaxis regimen
“Extending dosing let me work with my doctor to develop a dosing schedule that works for me.”
Watch Ray’s full story
Patients who started and stayed on prophylaxis prove IDELVION has powerful efficacy with both 7- and 14-day dosing‡
‡Of the 23 subjects in Arm 2, 19 were transitioned from on-demand to 7-day prophylaxis. The median AsBR during prophylaxis treatment was 0.7 (range: 0 to 4.2). Data for Arms 1 and 2 based on matched-pairs design.
References: 1. Gill JC, Roberts J, Li Y, Castaman G. Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B. Haemophilia. 2019. doi:10.1111/hae.13735. 2. Santagostino E, Martinowitz U, Lissitchkov T, et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016;127(14):1761-1769. doi:10.1182/blood-2015-09-669234.